Seikagaku Initiates a Phase III Clinical Trial (Additional Study) in the U.S. for SI-6603, Indicated for Treatment of Lumbar Disc Herniation
Consolidated Financial Results for the Thrid Quarter of Fiscal year 2017
Seikagaku will announce the financial results for the Third Quarter of the Fiscal Year ending March 31, 2018 at 15:00 on February 2, 2018.
Shared Research Inc. research report on our company has been updated
New Message from President